Phase 2 Clinical Trial of Intravenous Alvespimycin [KOS-1022] in Patients With Her2 Positive Breast Cancer

Trial Profile

Phase 2 Clinical Trial of Intravenous Alvespimycin [KOS-1022] in Patients With Her2 Positive Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2015

At a glance

  • Drugs Alvespimycin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Kosan Biosciences
  • Most Recent Events

    • 28 Oct 2008 Status changed from planning to discontinued, as reported by ClinicalTrials.gov.
    • 23 Oct 2008 New source identified and integrated (ClinicalTrials.gov record NCT00780000).
    • 28 Feb 2008 Kosan have reported that this trial will not be continued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top